Literature DB >> 11434453

Barnidipine.

H S Malhotra1, G L Plosker.   

Abstract

Bamidipine is an antihypertensive drug belonging to the dihydropyridine (DHP) group of calcium antagonists. It is available in a modified-release formulation which has a gradual onset of action and is effective in a single daily oral dose of 10 to 20 mg. Bamidipine has selective action against cardiovascular calcium antagonist receptors and its antihypertensive action is related to the reduction of peripheral vascular resistance secondary to its vasodilatory action. The clinical antihypertensive efficacy of barnidipine is similar to that of other DHP calcium antagonists such as nitrendipine and amlodipine, and antihypertensives belonging to other drug classes such as atenolol and enalapril. Barnidipine has been found to be as efficacious and well tolerated as hydrochlorothiazide in the management of hypertension in elderly patients. Barnidipine is generally well tolerated. As with other DHP calcium antagonists, vasodilator adverse events such as headache, flushing and peripheral oedema account for most of the adverse events reported with its use and are usually transient. Oedema is less frequent than with amlodipine and nitrendipine. Its use is not associated with reflex tachycardia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11434453     DOI: 10.2165/00003495-200161070-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  23 in total

1.  Treatment with a Ca(2+) channel blocker, barnidipine, reduces platelet-derived growth factor B-chain mRNA in glomeruli of spontaneously hypertensive rats.

Authors:  M Hashimoto; T Yamauchi; T Ogura; T Oishi; Y Mimura; F Otsuka; N Kashihara; H Makino
Journal:  Am J Nephrol       Date:  1999       Impact factor: 3.754

2.  Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation.

Authors:  T Teramura; T Watanabe; S Higuchi; K Hashimoto
Journal:  Xenobiotica       Date:  1997-02       Impact factor: 1.908

3.  Barnidipine monotherapy and combination therapy in older patients with essential hypertension: a long-term study.

Authors:  F B Naber; R Häge; J Mortelmans
Journal:  Int J Clin Pract Suppl       Date:  2000-11

4.  Barnidipine, a novel calcium antagonist for once-daily treatment of hypertension: a multicenter, double-blind, placebo-controlled, dose-ranging study. Dutch Barnidipine Multicenter Study Group.

Authors:  W Hart; N J Holwerda
Journal:  Cardiovasc Drugs Ther       Date:  1997-11       Impact factor: 3.727

5.  British Hypertension Society guidelines for hypertension management 1999: summary.

Authors:  L E Ramsay; B Williams; G D Johnston; G A MacGregor; L Poston; J F Potter; N R Poulter; G Russell
Journal:  BMJ       Date:  1999-09-04

6.  The role of renal hemodynamics in the antihypertensive action of mepirodipine, a new calcium antagonist.

Authors:  H Noda; T Fujita; E Ogata
Journal:  Jpn Circ J       Date:  1992-01

7.  A sustained occupancy in vivo of cardiovascular calcium antagonist receptors by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensive rats.

Authors:  S Yamada; Y Matsuoka; Y Kato; R Kimura; O Inagaki
Journal:  J Pharmacol Exp Ther       Date:  1992-08       Impact factor: 4.030

8.  Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension.

Authors:  I Kosegawa; M Inaba; T Morita; T Awata; S Katayama
Journal:  Clin Exp Hypertens       Date:  1998-10       Impact factor: 1.749

9.  Differential time course of the vasodilator action of various calcium antagonists.

Authors:  R van der Lee; K L Kam; M Pfaffendorf; P A van Zwieten
Journal:  Fundam Clin Pharmacol       Date:  1998       Impact factor: 2.748

10.  Distinct vasodilation, without reflex neurohormonal activation, induced by barnidipine in hypertensive patients.

Authors:  L Argenziano; R Izzo; G Iovino; N De Luca; L Parrella; C Morisco; B Trimarco
Journal:  Blood Press Suppl       Date:  1998
View more
  9 in total

1.  Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.

Authors:  Robert Lins; Yves Haerden; Caroline de Vries
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-03

2.  Effects of barnidipine on blood pressure and left ventricular diastolic function in patients with hypertension and metabolic syndrome: A 12-week, open-label noncomparison study.

Authors:  Fabio Angeli; Salvatore Repaci; Claudia Borgioni; Mariagrazia Sardone; Aurelio Scotti; Paolo Verdecchia
Journal:  Curr Ther Res Clin Exp       Date:  2008-06

3.  Antihypertensive effect of barnidipine 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension: A 24-week, randomized, open-label, pilot study.

Authors:  Giuseppe Rossetti; Samuele Pizzocri; Francesco Brasca; Marta Pozzi; Laura M Beltrami; Giovanni B Bolla; Roberta Famiani; Barbara Caimi; Stefano Omboni; Fabio Magrini; Stefano Carugo
Journal:  Curr Ther Res Clin Exp       Date:  2008-06

4.  Barnidipine Real-Life Efficacy and Tolerability in Arterial Hypertension: Results from Younger and Older Patients in the BASIC-HT Study.

Authors:  Robert Lins; Caroline De Vries
Journal:  Open Cardiovasc Med J       Date:  2017-11-17

5.  Dissolution method for delapril and manidipine combination tablets based on an absorption profile of manidipine.

Authors:  Vítor Todeschini; Maximiliano S Sangoi; Gustavo K Goelzer; Jaison C Machado; Clésio S Paim; Bibiana V Araujo; Nadia M Volpato
Journal:  J Pharm Anal       Date:  2015-10-23

Review 6.  New generations of dihydropyridines for treatment of hypertension.

Authors:  Angela L Wang; Costantino Iadecola; Gang Wang
Journal:  J Geriatr Cardiol       Date:  2017-01       Impact factor: 3.327

Review 7.  The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design.

Authors:  Yong Ling; Zhi-You Hao; Dong Liang; Chun-Lei Zhang; Yan-Fei Liu; Yan Wang
Journal:  Drug Des Devel Ther       Date:  2021-10-13       Impact factor: 4.162

8.  Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.

Authors:  Giuseppe Derosa; Amedeo Mugellini; Fabrizio Querci; Ivano Franzetti; Rosa Maria Pesce; Angela D'Angelo; Pamela Maffioli
Journal:  Sci Rep       Date:  2015-08-05       Impact factor: 4.379

9.  Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.

Authors:  Giuseppe Derosa; Amedeo Mugellini; Rosa Maria Pesce; Angela D'Angelo; Pamela Maffioli
Journal:  BMC Cardiovasc Disord       Date:  2016-04-12       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.